The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.
Chris Twelves
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Other Remuneration - Eisai
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Linda T. Vahdat
Consultant or Advisory Role - Eisai
Honoraria - Bristol-Myers Squibb; Eisai; Genomic Health
Martin S. Olivo
Employment or Leadership Position - Eisai
Yi He
Employment or Leadership Position - Eisai
Peter Andrew Kaufman
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Ahmad Awada
No relevant relationships to disclose